IL-10 Antibody (YA3521)

Interleukin-10 (IL-10) functions as a critical anti-inflammatory cytokine that modulates innate and adaptive immune responses^[1][2]. Mechanistically, IL-10 activates the JAK-STAT signaling pathway, particularly STAT3, to suppress proinflammatory cytokine production and promote immunoregulatory gene expression^[3][1]. In experimental models of bacterial sepsis, IL-10 partially restores mitochondrial function and oxidative phosphorylation in monocytes, counteracting pathogen-induced metabolic inhibition^[1]. T cell-derived IL-10 production is regulated by metabolic pathways, including aryl hydrocarbon receptor (Ahr) and Bhlhe40, which control cytokine output and mucosal immune homeostasis in intestinal inflammation models^[2]. Compared with related cytokines, IL-10 displays distinct anti-inflammatory potency and feedback regulation not shared by IL-6 or TNF-α^[3][1]. Agonists and inhibitors targeting upstream metabolic or signaling modulators, such as dichloroacetate (DCA), can selectively enhance IL-10 production in Th1 cells, demonstrating translational potential for inflammatory bowel disease research^[2]. Furthermore, IL-10 isoform-specific signaling contributes to differential regulation of oxidative phosphorylation genes, offering a mechanistic basis for isoform-focused experimental applications^[1]. Collectively, these findings highlight IL-10 as a central regulator of immune homeostasis, with mechanistic specificity distinct from related cytokines and amenable to pharmacological modulation in experimental and disease-relevant contexts^[3][1][2].